NextCure (NXTC) Revenue (2019 - 2020)
NextCure (NXTC) posted quarterly Revenue of $22.4 million for Q1 2020, up 1549.08% year-over-year from $1.4 million in Q2 2019, and up 1016.11% quarter-over-quarter from $2.0 million in Q4 2019.
NextCure (NXTC) Revenue (2019 - 2020) Analysis & Trends
NextCure's Revenue history runs 2 years deep, the most recent figure standing at $22.4 million for Q1 2020.
- In Q1 2020, Revenue rose 1549.08% year-over-year to $22.4 million; the TTM figure through Dec 2020 stood at $22.4 million (up 252.58% YoY), while the FY2020 annual figure was $22.4 million, up 252.58% from the prior year.
- Revenue for Q1 2020 stood at $22.4 million, up from $2.0 million in the prior quarter.
- The five-year high for Revenue was $22.4 million in Q1 2020, with the low at $1.4 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | NextCure | 34.14 Mn | 34.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 22.38 Mn |
| Dec 31, 2019 | 2.01 Mn |
| Sep 30, 2019 | 1.58 Mn |
| Jun 30, 2019 | 1.40 Mn |
| Mar 31, 2019 | 1.36 Mn |